TABLE 1.
Clinical characteristics of patients with adverse events under different administration routes of Semaglutide
| Characteristics | Subcutaneous of semaglutide | Oral of semagluti |
|---|---|---|
| X | Overall | Overall |
| (N = 16,346) | (N = 2,496) | |
| SEX,n (%) | ||
| F | 10,311 (63.1%) | 1,409 (56.5%) |
| M | 5,342 (32.7%) | 1,002 (40.1%) |
| Missing | 693 (4.2%) | 85 (3.4%) |
| WT (kg),n (%) | ||
| <50 | 11 (0.1%) | 18 (0.7%) |
| >100 | 635 (3.9%) | 93 (3.7%) |
| 50–100 | 1,055 (6.5%) | 238 (9.5%) |
| Missing | 14,645 (89.6%) | 2,147 (86.0%) |
| AGE (year),n (%) | ||
| <18 | 11 (0.1%) | 1 (0.0%) |
| >85 | 57 (0.3%) | 36 (1.4%) |
| 18–64.9 | 4,615 (28.2%) | 650 (26.0%) |
| 65–85 | 3,395 (20.8%) | 556 (22.3%) |
| Missing | 8,268 (50.6%) | 1,253 (50.2%) |
| COUNTRY,n (%) | ||
| US | 15,286 (93.5%) | 2045 (81.9%) |
| CN | 66 (0.4%) | 1 (0.0%) |
| CA | 185 (1.1%) | 5 (0.2%) |
| GB | 82 (0.5%) | 27 (1.1%) |
| DK | 102 (0.6%) | 21 (0.8%) |
| JP | 111 (0.7%) | 262 (10.5%) |
| Reporting year,n (%) | ||
| 2023 | 5,841 (36%) | 729 (29%) |
| 2022 | 3,954 (24%) | 707 (28%) |
| 2021 | 2,485 (15%) | 646 (26%) |
| 2020 | 2019 (12%) | 412 (17%) |
| 2019 | 1,037 (6%) | 2 (0%) |
| 2018 | 1,010 (6%) | |
| Outcome,n (%) | ||
| HO | 1778 (10.5%) | 390 (14.8%) |
| DE | 108 (0.6%) | 43 (1.6%) |
| DS | 191 (1.1%) | 39 (1.5%) |
| LT | 124 (0.7%) | 29 (1.1%) |
| CA | 2 (0.0%) | 1 (0.0%) |
| RI | 67 (0.4%) | 10 (0.4%) |
| OT | 3,432 (20.3%) | 577 (21.9%) |
| Missing | 11,245 (66.4%) | 1,546 (58.7%) |
Note: n, number of cases with available.